Psilocybin prevents reinstatement of alcohol seeking by disrupting the reconsolidation of alcohol-related memories.
F Benvenuti, D Colombo, L Soverchia, N Cannella, E Domi, R Ciccocioppo
Psychopharmacology July 1, 2023 DOI: 10.1007/s00213-023-06384-w via PubMed
Summary
AI-generated from the abstractIn a rat model of alcohol use disorder, psilocybin did not reduce alcohol consumption, prevent relapse after forced abstinence, or block cue-induced reinstatement of alcohol seeking. However, when administered during a memory retrieval-reconsolidation paradigm, psilocybin markedly attenuated the resumption of alcohol seeking. These findings suggest that psilocybin may be effective for disrupting the reconsolidation of alcohol-related memories, opening possibilities for clinical use where patients recall alcohol memories and then receive psilocybin during the reconsolidation phase.
Study at a glance
| Characteristics | Preclinical experimental study Peer reviewed |
|---|---|
| Population | Male and female Marchigian Sardinian alcohol-preferring (msP) rats |
| Intervention | Psilocybin |
| Topics | Addiction Psychedelic-assisted therapy |
| Keywords | Alcoholism Psychedelics Reward Addiction treatment |
| Citations | 14 |
| Key finding | Psilocybin did not reduce alcohol consumption or relapse but markedly attenuated resumption of alcohol seeking when given during a memory retrieval-reconsolidation paradigm. |
Abstract
For most psychiatric conditions, including alcohol use disorder (AUD), FDA-approved pharmacological treatments are limited and their efficacy is restricted to only certain subgroups of patients. Scientific interest in the potential of psychedelic drugs has dramatically increased because of clinical preliminary evidence of efficacy in treating various psychiatric disorders. One of the most promising compounds belonging to this class of molecules is psilocybin. Here, to elucidate the therapeutic potential and treatment modalities of this drug, we investigated the effect of psilocybin on alcohol drinking and seeking in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats, a well validated animal model of AUD characterized by excessive drinking and seeking. Using male and female msP rats, we tested the effect of psilocybin on home cage voluntary alcohol consumption. We also tested the effect of the drug on the alcohol deprivation effect (ADE) model of relapse and on cue-induced reinstatement of alcohol seeking after a period of abstinence. Finally, we evaluated if psilocybin may disrupt the reconsolidation process of alcohol-related memory. Psilocybin did not reduce alcohol consumption, nor it prevented increased alcohol drinking after a period of forced abstinence and cue-induced reinstatement of alcohol-seeking. Noteworthy, in a memory retrieval-reconsolidation paradigm, psilocybin markedly attenuated resumption of alcohol seeking. Altogether these data suggest that, despite psilocybin does not affect alcohol drinking and relapse, it may be highly effective if used to block the reconsolidation process of alcohol-related memories. This opens to the possibility of using this psychedelic drug in clinical settings in which AUD patients undergo procedures to recall the memory of alcohol and are then treated with psilocybin during the memory reconsolidation phase.